Efficacy and Safety of Ipilimumab Plus Anti-PD-1/PD-L1 Antibodies Combination Therapy in Advanced Hepatocellular Carcinoma Patients Progressing After Multiple Lines of Treatment: A Retrospective Multicenter Study.

J Hepatocell Carcinoma · 2025 · PMC11910043 · PMID 40092399

Europe PMC DOI

hedged sentence

0.1200

closest p · 2.4× alpha

0.1200

boldest claim

The sentences

did not reach statistical significanceP=0.12not close (p > 0.1)

Survival analysis indicated a trend towards prolonged overall survival (OS) in patients receiving the 6-week regimen compared to the 3-week regimen, although this did not reach statistical significance (P=0.12 for OS, P=0.42 for PFS) ( Figure 1c and d ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.